Allergan Shares
- All
- News
-
Cipla Divests 16.7% Stake In Chase Pharma To Allergan
Delaware-based Chase Pharmaceuticals Corporation, in which the company's UK arm Cipla (EU) Ltd has 16.7 per cent stake, has been acquired by a subsidiary of Allergan plc, Cipla said in a statement.
-
Dr Reddy's Laboratories To Buy 8 Drugs From Teva Pharmaceutical, Shares Gain
The combined sales of the branded versions of the products in the US is around $3.5 billion, Dr Reddy's added.
-
Wall Street Ekes Out Gain, Helped by Consumer Stocks
US stocks eked out small gains on Monday morning, helped by gains in materials and consumer stocks, as investors stayed cautious after last week's strong gains and ahead of Thanksgiving.
-
Pfizer, Allergan Combining in $160 Billion Deal to Become Largest Drugmaker
Pfizer and Allergan will join in a $160 billion deal to create the world's largest drugmaker.
-
Lupin gains on US approval for eye drop generic
Shares in Lupin Ltd gained 3.2 per cent after the company got the final approval from the U.S. Food and Drug Administration for a generic version of eye drop Gatifloxacin on Friday, according to the web site of the US regulator.
-
Cipla Divests 16.7% Stake In Chase Pharma To Allergan
Delaware-based Chase Pharmaceuticals Corporation, in which the company's UK arm Cipla (EU) Ltd has 16.7 per cent stake, has been acquired by a subsidiary of Allergan plc, Cipla said in a statement.
-
Dr Reddy's Laboratories To Buy 8 Drugs From Teva Pharmaceutical, Shares Gain
The combined sales of the branded versions of the products in the US is around $3.5 billion, Dr Reddy's added.
-
Wall Street Ekes Out Gain, Helped by Consumer Stocks
US stocks eked out small gains on Monday morning, helped by gains in materials and consumer stocks, as investors stayed cautious after last week's strong gains and ahead of Thanksgiving.
-
Pfizer, Allergan Combining in $160 Billion Deal to Become Largest Drugmaker
Pfizer and Allergan will join in a $160 billion deal to create the world's largest drugmaker.
-
Lupin gains on US approval for eye drop generic
Shares in Lupin Ltd gained 3.2 per cent after the company got the final approval from the U.S. Food and Drug Administration for a generic version of eye drop Gatifloxacin on Friday, according to the web site of the US regulator.
